PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Simply rounding up the value of online purchases to the nearest pound and enabling users to save money into a digital wallet. Wishwallet aims to solve the problem of online shopping trolley abandonment, whereby consumers tend to leave products in their online baskets, but not continue to the checkout stage. The company aims to reduce this issue, whilst at the same time allowing customers to afford products and services they not have been able to before.
Wishwallet's revenue stream is comprised of service fees to retailers, advertisements, recurring subscriptions and data. The company aims to launch their service with access to more than 1,500 retailers. They have already completed Phase 1 of their app development cycle and following this investment round, they aim to complete their product to be ready to launch in early 2019. Any additional contributions will be used for marketing campaigns, key hires and future app upgrades.
days to go:
Expired
investment:
£122,140
Incorporated in Luxembourg in July 2018, Glu is a friendly, free-to-use community where users can explore the 'cryptoverse'. Glu is the 'TripAdvisor' for cryptocurrencies or the 'Money Super Market' of crypto exchanges. It serves as a guide to its users through a world full of jargon, mistrust and disjointed information about cryptocurrencies. Glu is working on an integrated B2B & B2C strategy for revenue. It aims to develop B2B customers and build website traffic and then focus on B2C revenues. 41% of the proceeds will be used for product development, 26% for Operations and Customer Support, 17% for Sales and Marketing, and 16% for G&A.
days to go:
Expired
investment:
£158,319
Currikulo is an online platform designed to improve the recruitment process. Currikulo allows the employer to easily create a microsite which explains what the company does and also lists job description and the skills needed. All the employee has to do is fill out their skills and previous projects they have worked on and Currikulo will show a list of jobs they are qualified to do globally.
days to go:
Expired
investment:
£20,030
Meetzoo is a mobile app that is designed to help people manage their business meetings and time more effectively. Meetzoo users can see information about people they meet, whether they've met before, collaborate on agenda items, notes and quickly see any outstanding actions from previous meetings.
days to go:
Expired
investment:
£144,640
B-North intends to revolutionise the business lending industry, which is often outdated, impersonal and slow. The fintech company uses some of the most advanced cloud-based technology, coupled with face-to-face relationship teams to get the best lending solutions for borrowers and their businesses. The company is powered by a team with prior experience in starting and scaling challenger banks, and profitability is its focused goal. B-North has submitted the banking licence application, and the result is expected by 2020.
days to go:
Expired
investment:
£2,135,456
Myn is an innovative source-to-pay platform driven by AI, aiming to establish a seamless network connecting companies, workers, and recruiters. Their end-to-end solution encompasses intelligent talent sourcing, self-service talent acquisition, fully funded payrolling services, digital compliance solutions, job boards, and enticing employee benefits.
days to go:
Expired
investment:
£939,520
